Tumor progression is a multiple step process in which, in addition to oncogenic mutation, other supporting factors can contribute to transformation. The role these factors have in cancer is an open question. Using the El-myc model of B-cell transformation, we evaluated the contribution of the cytokine interleukin-7 (IL-7) in supporting lymphomagenesis. We have previously shown that disruption of the Y449xxM motif of the IL-7 receptor alpha (IL-7Ra) in a knock-in mouse model ) has minor effects on lymphocyte production, but interferes with the activation of survival effectors. To address the hypothesis that targeted signal ablation would selectively affect lymphocyte transformation, IL-7Ra 449F mice were crossed with two lymphomagenesis models, transgenic (Tg) IL-7 and El-myc mice. We found that the loss of IL-7Ra Y449 signaling prevented Tg IL-7-mediated T-and B-lymphocyte transformation and decreased the development of El-myc-induced B-cell tumors. We showed that the IL-7Ra 449F mutation prevented increased survival of Tg IL-7 CD8 T cells, and decreased viability of bone marrow progenitor B cells, as well as Elmyc-induced proliferation. This study shows that IL-7Ra Y449 is important for lymphocyte transformation, and that unlike deficiencies in pre-B cell receptor signaling, Myc overexpression cannot compensate for the loss of IL-7Ra signals in early B-cell development.
Introduction
Leukemia and lymphoma account for 700 000 cancer cases annually. These remain the leading cause of disease-related deaths in children with secondary health drawbacks for survivors (Canadian Cancer Society/ National Cancer Institute of Canada, 2008) . Immunotherapies that target cancer while minimizing damage to surrounding lymphocytes and tissues could improve patient outcome. The cytokine interleukin-7 (IL-7) has been identified as a supportive factor for several human lymphocyte malignancies, including Hodgkin's and both B-and T-cell acute and chronic lymphocytic leukemias (Touw et al., 1990; Foss et al., 1995; Long et al., 1995; Barata et al., 2001 Barata et al., , 2004 Juarez et al., 2007; Scupoli et al., 2007; Cattaruzza et al., 2009; Sasson et al., 2010) . Along with Notch ligands and c-kit, IL-7 has a prominent, essential role in early T-and B-cell fate determination. The role of survival and other signals induced by deregulation of this primary lymphoid cytokine in determining tumorigenesis is unknown.
In murine B-cell development, cooperative signals initiated from the pre-B-cell receptor (pre-BCR) and IL-7 receptor (IL-7) govern pre-B-cell proliferation during heavy chain rearrangement to allow differentiation and maturation. c-Myc is a transcription factor that has a key role in regulating B-lymphocyte differentiation and expansion (Habib et al., 2007) . Overexpression of c-Myc in the Em-myc mouse causes transformation of pre-B cells (Adams et al., 1985) and is a well-defined model for human B lymphomagenesis. Similarly, transgenic overexpression of IL-7 (Tg IL-7) caused mixed T-and B-cell lymphomas that arose by oligoclonal expansion of variable subsets, which could form masses upon transfer to either immunocompetent or nude mice (Rich et al., 1993) . As IL-7 is essential for both T-and B-cell development in mice and T cells in humans (Peschon et al., 1994; von Freeden-Jeffry et al., 1995; Kovanen and Leonard, 2004) , we aimed to determine whether the signals necessary for lymphocyte homeostasis and development could be separated from those required for transformation.
IL-7 signaling is transduced by IL-7R, a heterodimer composed of the g-common chain (CD132, shared receptor component for cytokines IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) and IL-7Ra (CD127, also shared with the thymic stromal lymphopoietin receptor). IL-7Ra has a conserved tyrosine residue, Y449, located in an SH2 domain-binding motif (YXXM), required for the activation of signal transducer and activator of transcription 5 (STAT5) and the phosphoinositide 3 (PI3) kinase/Akt pathway (Pallard et al., 1999; Wofford et al., 2008) . In contrast to IL-7Ra knockout mice that are severely lymphopenic because of developmental blocks in both B-and T-cell lineages (Peschon et al., 1994) , mice with a targeted Y449 to phenylalanine (F) knock-in mutation at the IL-7Ra locus ) show relatively normal T-cell differentiation . As the IL-7Ra 449F mutation allows T-cell differentiation but alters the signaling capacity of the receptor, we tested the hypothesis that IL-7Ra Y449-mediated pathways were essential for lymphoid transformation.
We crossed IL-7Ra 449F mice with the Tg IL-7 model and the Em-myc model to evaluate the role of IL-7Ra signaling in T-and B-cell development and transformation. We determined that specific elimination of IL-7Ra Y449-mediated signaling was sufficient to prevent lymphomagenesis in the Tg IL-7 model and surprisingly, caused significantly lower c-Myc-driven mortality. In the Tg IL-7 model, T-cell transformation is associated with altered regulation of Bcl-2 family members and increased CD8 T-cell survival. We determined that the IL-7Ra 449F mutation prevented lymphomagenesis and normalized the expression of Bcl-2 family members without severe detriment to lymphocyte development. Analysis of Em-myc; IL-7Ra 449F B-cell progenitors revealed that the IL-7Ra 449F mutation rendered them less viable, unable to activate STAT5 in response to IL-7 and resistant to Em-myc-induced proliferation. Thus, we show that interference with IL-7Ra Y449 signaling impairs lymphomagenesis in both B and T cells using two distinct genetic models.
Results
Abrogation of IL-7Ra Y449 signals protects from IL-7-mediated lymphomagenesis Tg IL-7 mice have been previously used to study IL-7-responsive tumor types and IL-7-mediated transformation (Rich et al., 1993; Abraham et al., 2005) . To investigate the requirement of IL-7Ra Y449 signaling in IL-7-mediated lymphomagenesis, we generated Tg IL-7 IL-7Ra þ / þ , IL-7Ra þ /449F and IL-7Ra 449F animals. Tg IL-7; IL-7Ra þ / þ mice developed lymphoid tumors and had a median mortality of 24 weeks (Figure 1a) . Strikingly, replacement of wild-type (wt) IL-7Ra with one mutated allele (Tg IL-7; IL-7Ra
) doubled the median survival age (47 weeks). Mice expressing both copies of the mutated IL-7Ra 449F allele were completely protected (465 weeks) (Figure 1a ). Spleens from endstage Tg IL-7; IL-7Ra
were hypertrophic with expanded white pulp areas, whereas age-matched Tg IL-7; IL-7Ra 449F spleens had normal white and red pulp separation (Supplementary Figure 1a) . These differences occurred despite comparable levels of thymic IL-7 mRNA expression in Tg IL-7; IL-7Ra þ / þ and Tg IL-7; IL-7Ra 449F littermates (Supplementary Figure 1b) . This suggested that IL-7Ra Y449 signaling was essential for lymphocyte transformation. Y449 signaling is essential for IL-7-induced  splenomegaly and CD8 T-cell expansion but does not  alter lymphoma precursor populations  To determine the effects of Tg IL-7 and IL-7Ra   449F mutations, we assessed lymphocyte differentiation in the thymi and spleens of 8-week-old wt, IL-7Ra 449F , Tg IL-7; IL-7Ra þ / þ and Tg IL-7; IL-7Ra 449F mice. As previously shown, the IL-7Ra 449F mutation allowed T-cell differentiation and CD4/CD8 profiles similar to wt in both the thymus and the spleen, although cellularity was decreased (Figures 1b and c) . In contrast, at 8 weeks and with no detectable lymphocyte transformation, Tg IL-7; IL-7Ra þ / þ mice had significant abnormalities in subset composition. IL-7 overexpression resulted in increased frequency and number of CD8 single-positive (SP) thymocytes, development of an abnormal thymic
IL-7Ra
) and decreased frequency and number of CD4 þ CD8 þ double-positive (DP) cells (Figures 1b and c) . At the same time, an abnormal population of DP cells was present in the spleens of Tg IL-7; IL-7Ra þ / þ mice ( Figure 1b , bottom panel), and splenomegaly had developed due to increased peripheral CD4 and CD8 T cells and B cells (Figure 1c , bottom panel). Chronic IL-7 overexposure resulted in the development of fatal thymomas or peripheral lymphoid tumors that were primarily composed of DP and CD8 SP T cells (Supplementary Table 1 ).
Despite the fact that IL-7 overexpression allowed for significant IL-7Ra Y449-independent increases in lymphocyte cellularity, the IL-7Ra 449F mutation prevented Tg IL-7-induced developmental defects noted above and resulted in thymic and peripheral lymphocyte differentiation similar to wt. Remarkably, CD8 T-cell expansion was prevented, the frequency of thymic B cells was decreased and splenic DP cells were absent in Tg IL-7; IL-7Ra 449F mice (Figures 1b and c) . Most importantly, these mice did not develop splenomegaly (Figures 1b and c, bottom panel) or succumb to tumorinduced mortality (Figure 1a) . Although the transformation target population is not clearly defined in the Tg IL-7 model, DN, CD4 and CD8 T-cell pools were equivalent between Tg IL-7; IL-7Ra þ / þ and Tg IL-7; IL-7Ra 449F mice making target size of these cell types an unlikely factor (Figure 1c ).
IL-7Ra Y449 is required for IL-7-mediated increases in cell survival As CD8 T-cell development was dramatically affected before disease and these cells were the predominant subset in lymphomas, the CD8 T-cell lineage of Tg IL-7; IL-7Ra þ / þ mice was further analyzed for biochemical changes that would explain their preferential growth characteristics. Expression of the IL-7-regulated antiapoptotic protein Bcl-2 was consistently increased in predisease samples of Tg IL-7; IL-7Ra þ / þ DP and CD8 SP thymocytes (Supplementary Figure 2a) . In peripheral CD4 and CD8 T cells, transgenic IL-7 increased the expression of Bcl-2 and Bcl-xL through IL-7Ra Y449, but did not affect expression of Mcl-1 or We then compared the expression of Bcl-2 in Tg IL-7; IL-7Ra þ / þ thymomas and age-matched, healthy Tg IL-7; IL-7Ra þ / þ and Tg IL-7; IL-7Ra 449F thymocytes and found that the increase noted in healthy samples was exaggerated in frank lymphomas, particularly in DP and CD8 SP thymocyte populations and that this Figure 2c) . Interestingly, Bim downregulation was noted in one Tg IL-7; IL7Ra þ / þ thymoma analyzed (data not shown), suggesting that IL-7 may affect lymphoid transformation through Bcl-2/Bim imbalance. Thus, deregulation of Bcl-2 family members, specifically in DP and CD8 T cells, is characteristic of IL-7-mediated transformation and is dependent on the IL-7Ra Y449xxM motif.
To determine the functional consequence of differential anti-apoptosis effector expression, we exposed splenic lymphocytes from wt, IL-7Ra 449F , Tg IL-7; IL7Ra
and Tg IL-7; IL-7Ra 449F mice to various apoptotic stimuli and measured the percentage of viable cells after treatment. IL-7 overexpression provided a survival advantage to dexamethasone-treated or cytokine-starved CD8 T cells and this protection was IL7Ra Y449 dependent ( Figure 2c ; Supplementary Figure  2d) . Interestingly, CD4 SP T cells and B cells were not protected from dexamethasone-induced apoptosis (data not shown). However, Tg IL-7 CD8 T cells were still susceptible to free radical-induced apoptosis, despite the finding that ectopic Bcl-2 expression can be protective in this setting (Supplementary Figure 2d ; Hockenbery et al., 1993) .
Analysis of proliferation using Ki67 expression in predisease samples from Tg IL-7; IL-7Ra þ / þ and agematched wt controls suggested that the IL-7 transgene had a less profound effect on proliferation than cell survival. In agreement with previous data (El Kassar et al., 2004) , Tg IL-7; IL-7Ra
) thymocytes had fewer Ki67 þ cells than did wt IL-7Ra Y449 signals contribute to lymphomagenesis LC Osborne et al counterparts ( Figure 2d ). In contrast, there was a paradoxical increase in Ki67 þ DN thymocytes in Tg IL-7; IL-7Ra 449F mice over wt controls (Figure 2d ), consistent with our previous findings (Duthie et al., 2007) . Increased DN proliferation could contribute to the increased number of DP thymocytes in these mice (Figure 1c) . However, at later stages of thymocyte development, IL-7 overexpression has minimal effects on Ki67 expression. Notably, neither Tg IL-7; IL-7Ra
nor Tg IL-7; IL-7Ra 449F CD8 SP thymocytes (Figure 2d ) or peripheral T or B cells show significant changes in Ki67 expression compared with wt counterparts (data not shown). These data suggest that the antiapoptosis signals relayed through the IL-7Ra Y449 residue may allow the accumulation of secondary genetic lesions required for lymphocyte transformation.
c-Myc lymphomagenesis is reduced by the IL-7Ra 449F mutation We next evaluated whether disrupted IL-7Ra Y449 signaling could confer protection in Em-myc mice, a murine B-cell lymphoma model of human Burkitt's lymphoma (Adams et al., 1999) . Em-myc; IL-7Ra þ / þ , Em-myc; IL-7Ra þ /449F and Em-myc; IL-7Ra 449F mice were generated. Strikingly, a single-mutated IL-7Ra allele provided significant protection, and expressing two mutated copies increased the median survival time from 15.5 to 66.5 weeks (Figure 3a) . To ensure that the differences in transgene expression were not the cause of the delayed tumor onset in Em-myc; IL-7Ra 449F mice, we quantified c-Myc in tumors isolated from Em-myc; IL-7Ra þ / þ and Em-myc; IL-7Ra 449F mice and found that the expression was similar (Figure 3b ). This genetic analysis indicated that IL-7Ra signals involved in B lymphopoiesis were critical for the emergence of Em-myc-induced tumors.
Overexpression of the c-Myc oncoprotein results in developmental arrest and pre-B-or B-cell lymphomas (Adams et al., 1985; Langdon et al., 1986) . As IL-7Ra 449F mice have decreased numbers of peripheral B cells , it was possible the Em-myc; IL-7Ra 449F mice were protected from c-Myc-induced lymphomagenesis due to a decreased population of lymphoma precursors. We quantified B-cell progenitor populations in the bone marrow (BM) of predisease Em-myc and nontransgenic IL-7Ra þ / þ and IL-7Ra 449F mice at 6 weeks of age (Figure 3c ). In agreement with previous findings (Langdon et al., 1986) , the pre-B subset was greatly expanded in Em-myc; IL-7Ra þ / þ mice compared with non-Tg controls. In contrast, the IL7Ra 449F mutation resulted in decreased numbers of pre-B and mature B cells compared with wt. The combination of these two alterations in Em-myc; IL-7Ra 449F mice IL-7Ra Y449 signals contribute to lymphomagenesis LC Osborne et al resulted in pre-B-cell numbers similar to wt. Thus, the IL-7Ra 449F mutation does decrease the target population and could contribute to delayed lymphomagenesis.
449F mutation inhibits essential progenitor B-cell survival and proliferation signals To determine whether factors other than decreased B-cell cellularity contributed to the protection in Emmyc; IL-7Ra 449F mice, we analyzed B-cell subsets for survival and proliferation defects. As hyperproliferation is a hallmark of Em-myc-induced tumors (Adams et al., 1999) , we evaluated proliferation of BM and splenic B-cell subsets using expression of Ki67 as a marker. As expected, Em-myc; IL-7Ra þ / þ B cells expressed high levels of Ki67 more frequently than did wt counterparts (Figure 4a) . Interestingly, fewer Em-myc; IL-7Ra 449F B cells were Ki67 þ (Figure 4a ), indicating that the IL-7Ra 449F mutation interfered with c-Myc-induced proliferation and likely contributes to the protection noted in these mice.
However, a paradoxical finding was that the IL-7Ra 449F mutation actually increased the frequency of Ki67 þ cells compared with wt in BM B progenitors ( Figure 4a ). As the cellularity of this compartment was decreased, we aimed to determine whether cell viability was compromised. Bcl-2 expression was used as a measure of antiapoptosis capacity. At the earliest stages of B-cell development, no significant differences in Bcl-2 expression were detected between mice of all genotypes (Figure 4b ). However, as B cells matured, mice bearing the IL-7Ra 449F mutation had higher Bcl-2 expression (mature BM cells shown in Figure 4b , data not shown for splenic B cells), despite the absence of expression of IL-7Ra in mature B cells (Marshall et al., 1998; Wei et al., 2000; Supplementary Figure 4) . In agreement with previous findings (Eischen et al., 2001a, b) , mature splenic B cells of predisease Em-myc; IL-7Ra þ / þ mice downregulated the antiapoptotic Bcl-2 protein compared with wt (data not shown).
To determine whether changes in Bcl-2 expression had a functional consequence, viability of progenitor and splenic B cells from wt, IL-7Ra 449F , Em-myc; IL-7Ra
and Em-myc; IL-7Ra 449F mice was determined directly ex vivo. IL-7Ra 449F and Em-myc; IL-7Ra 449F mice had significantly fewer viable cells in the pre-B-and mature B-cell compartments, indicating a clear survival defect due to the loss of IL-7Ra Y449 signaling (Figure 4c ) independent of Bcl-2 levels. Thus, IL-7Ra 449F B cells are not protected from apoptosis, indicating that increased Bcl-2 expression may not correlate with increased susceptibility to transformation in B cells.
To determine whether IL-7 signaling pathways known to be important for B-cell development were affected in IL-7Ra 449F mice, we monitored STAT5 activation in BM B-cell progenitors. As with our previously reported analysis of T cells, STAT5 activity in B cells required phosphorylation of IL-7Ra Y449 (Figure 4d ). We failed to detect IL-7-induced immediate, early activation of PI3 kinase by Akt phosphorylation in primary B-cell progenitors (data not shown). This is consistent with data showing that PI3 kinase p110d activity is not Figure 6) . Taken together, these data show that the IL-7Ra 449F mutation delays c-Myc-induced tumor onset by interfering with pre-B-cell viability and proliferation induced by c-Myc overexpression.
c-Myc tumors retain IL-7 responsiveness but become IL-7 independent
To determine whether the IL-7Ra 449F mutation affected the course of lymphomagenesis, we performed histopathological and flow cytometric analyses of B-cell stages on tumors collected from end-stage mice. Em-myc; IL-7Ra þ / þ tumors had a Burkitt-like lymphoma with morphology similar to that seen in human disease with prominent apoptotic cell death and a high frequency of mitotic cells (Figure 5a ). This typical 'starry-sky' pattern was also seen in affected lymphoid organs of Em-myc; IL-7Ra þ /449F and Em-myc; IL-7Ra 449F animals in the majority of cases (data not shown; Figure 5a ). In agreement with previous findings (Adams et al., 1985) , Em-myc; IL-7Ra þ / þ tumors were composed of either pre-B or mature B cells, and this was also the case for the majority of the Em-myc; IL-7Ra 449F tumors (Supplementary Table 2 ). In addition, IL-7Ra 449F mutation did not affect the characteristic hyperproliferation induced by c-Myc in these end-stage tumors (data not shown).
To determine whether Em-myc tumors retain IL-7Ra Y449 dependency after transformation, cells harvested from Em-myc; IL-7Ra
and Em-myc; IL-7Ra 449F tumors were transplanted to wt mice and hosts monitored for survival. In this analysis, comparing growth rates of two Em-myc; IL-7Ra þ / þ and one Em-myc; IL-7Ra 449F tumors, the Em-myc; IL-7Ra 449F tumor had no impairment of tumor growth and was in fact more aggressive and caused rapid morbidity (Figure 5b ). This suggested that frank lymphomas can bypass the requirement for IL-7Ra Y449 signals. To more generally determine whether IL-7 signaling has a role in Em-myc tumor progression, Em-myc; IL-7Ra
tumor cells were transplanted to congenic hosts and the mice were treated with either neutralizing anti-IL-7 antibody or an isotype control. The tumor chosen for analysis (Em-myc 1409), was IL-7Ra þ and demonstrated IL-7 responsiveness in vitro (Figure 5c ). Despite effective IL-7 neutralization shown by host-derived BM progenitor B-cell lymphopenia in anti-IL-7-treated mice (Figure 5d) , tumors grew to similar size over the treatment period supporting an IL-7-independent growth phase at this stage. Taken together, these data suggest that although the IL-7Ra 449F mutation inhibits IL-7-mediated B-cell progenitor survival and Em-mycinduced proliferation to delay transformation, it does not affect late-stage disease. þ / þ tumors were tested for IL-7 responsiveness in vitro. Cells were treated with or without 10 ng/ml IL-7 for 24 h, with 10 mM BrdU added for the last hour of incubation and then analyzed for BrdU incorporation by flow cytometry. (d) 5 Â 10 6 live cells from the IL-7-responsive Em-myc; IL-7Ra þ / þ tumor (Em-myc 1409) were transplanted i.v. into congenic CD45.1 þ hosts. The next day, and every second day thereafter for a total of five treatments, mice received 500 mg of either neutralizing anti-IL-7 or an isotype-matched control antibody. At the end of 10 days, the BM and spleens were harvested. CD45.1 þ host BM progenitor B cells were quantified (left panel) to show blockade of IL-7 function. CD45.2 þ donor tumor cells were quantified in the spleens of recipient mice (right panel).
IL-7Ra Y449 signals contribute to lymphomagenesis LC Osborne et al IL-7Ra 449F mice retain cell extrinsic susceptibility to tumors To determine whether IL-7Ra 449F mice are protected from IL-7-and c-Myc-mediated lymphomagenesis as a result of cell extrinsic effects such as greater tumor surveillance and clearance of developing tumors, we transplanted established tumorigenic cell lines into wt and IL-7Ra 449F mice and monitored survival of the host mice. Two aggressive syngeneic murine T-cell lymphoma cell lines were tested (RMA and EL4), and in both cases, wt and IL-7Ra 449F mice were equally susceptible to transplanted tumor cells (Figure 6a ; data not shown). To directly test whether Myc-induced lymphoma were differentially cleared, this experiment was performed with spontaneously arising Em-myc; IL-7Ra þ / þ tumor cells transplanted intravenously into wt and IL-7Ra 449F mice. As with RMA cells, wt and IL-7Ra 449F mice were equally susceptible to transplanted tumor cells (Figure 6b ). This experiment was repeated with three different Em-myc-derived tumors and the results were comparable for each experiment. PCR analysis of recovered tumor cells confirmed that they were carrying the Em-myc transgene and thus derived from transplanted cells, whereas analysis of tail biopsies confirmed that host mice were nontransgenic (Figure 6c ). These data show that the host milieu was not responsible for the protection in these mice and suggest that cell intrinsic IL-7Ra-dependent signals are essential for early lymphomagenesis.
Discussion
IL-7 and its downstream signaling effectors PI3 kinase, STAT5, Bcl-2 and Mcl-1 have been implicated in human leukemia and lymphoma. We undertook this study to determine how lymphomagenesis was affected when IL-7-mediated activation of such pathways was compromised. Perhaps unsurprisingly, IL-7Ra 449F mutation completely abrogates tumor development in Tg IL-7 mice. More significantly, it also delays tumor onset in Em-myc mice. In both lymphoma models, we see dosedependent protection mediated by IL-7Ra 449F disruption, in which the substitution of one allele is sufficient to significantly delay disease progression. Although it is possible that IL-7Ra 449F mice bear a differentiation impairment that contributes to tumor latency, acute ablation of this motif or signaling effectors recruited to it would be required to determine this. The protection conferred in two distinct lymphoma models and the fact that one mutated allele of this motif significantly affects tumor latency in the absence of developmental or cellularity deficiencies in both models (data not shown) make it more likely to be due to signaling changes.
The Em-myc transgenic mouse model results in lymphoid transformation by hyperproliferation and secondary genetic lesions sustained during successive cell cycles (Adams et al., 1985 (Adams et al., , 1999 . Pro-and pre-B cells respond to cooperative pre-BCR and IL-7Ra signaling for optimal proliferation during heavy chain rearrangement (Marshall et al., 1998; Fleming and Paige, 2002) , and manipulation of these pathways can affect c-Myc-induced tumor development. For example, recombination activating gene (RAG) is required for pre-BCR surface expression that induces the maturation of pro-to pre-B cells and c-Myc-mediated cellular proliferation (Yasuda et al., 2008) . However, transgenic expression of c-Myc in rag2 À/À mice bypasses the requirement for pre-BCR signaling and gives rise to cells with a pre-B-cell phenotype (Habib et al., 2007) . 
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These data explain the fact that rag1 À/À mice, which normally have a developmental block at the pro-B-cell stage and therefore have dramatically decreased numbers of Em-myc lymphoma precursors, not only developed Em-myc-induced pre-B-cell lymphomas but also showed earlier tumor onset (Nepal et al., 2008) . Similarly, the loss of the BCR signaling effector phospholipaseCg2 shortens the lifespan of Em-myc mice due to an increase in BM pre-B cells that are hypersensitive to IL-7-induced proliferation (Wen et al., 2006) . These studies show that c-Myc overexpression is sufficient to overcome a pre-BCR-mediated developmental abnormality and that c-Myc and IL-7 cooperation can enhance oncogenic potential. In this study, we showed that IL-7Ra Y449 is essential for synergistic IL-7Ra/pre-BCR signaling as the IL-7Ra 449F mutation reduces pre-B-cell viability and inhibits c-Myc-induced proliferation, which together significantly delays tumorigenesis in a lymphocyteintrinsic manner.
A large body of work has addressed the molecular requirements of c-Myc-induced lymphomas and other than the p19 ARF /Mdm2/p53 axis, few molecules have been shown to be essential to this process (Eischen et al., 1999) . For example, nuclear factor-kB, the tumorsuppressor Ink4c, the death protein Apaf1/caspase9, as well as the DNA-modifying enzymes AID and Rag have all been shown to be dispensable for c-Myc-driven tumorigenesis (Scott et al., 2004; Keller et al., 2005; Kotani et al., 2007; Nilsson et al., 2007; Nepal et al., 2008) . However, our data show that signals through IL7Ra Y449, such as STAT5, can regulate transformation in this lymphoma model.
The IL-7 transgene has profound effects on lymphocyte development causing CD8 T-cell expansion and abnormal appearance of peripheral DP T cells and thymic B cells. Although the IL-7Ra 449F mutation prevented these developmental abnormalities, Tg IL-7; IL-7Ra 449F mice had significantly elevated thymic cellularity. Other cytoplasmic tyrosine residues of IL-7Ra or the JAK kinases may be involved in restoring survival and proliferation signals to T-cell progenitors.
Molecular changes in response to chronic IL-7 exposure in Tg IL-7 mice leads to tumor development, most commonly T-lineage cells with a CD8
Tg IL-7-mediated lymphomas appear to arise from long-lived cells that upregulate antiapoptotic Bcl-2 family members and become resistant to apoptosis. In contrast, elevated Bcl-2 in IL-7Ra 449F B cells failed to confer increased cellular viability in IL-7Ra 449F BM progenitors. This is reminiscent of IL-7Ra 449F memory T cells that are not maintained despite similar levels of Bcl-2 expression and suggests that Bcl-2 is not sufficient to ensure survival in all cell types. Although Bcl-2 upregulation is seen in over half of c-Myc-induced tumors (Eischen et al., 2001b) , loss of Bcl-2 does not significantly impact the lifespan of Em-myc mice (Kelly et al., 2007) . Whether specific disruption of Bcl-2 (or Bcl-xL) in Tg IL-7 mice would similarly result in tumors that acquire antiapoptotic capability by other molecular means remains to be addressed.
We have previously demonstrated in thymocytes and T cells that IL-7Ra Y449 is dispensable for the upregulation of Bcl-2 following acute IL-7 stimulation, although baseline Bcl-2 expression is lower in IL-7Ra 449F cells . Our current findings support a model in which IL-7Ra Y449 signaling has an important role in the regulation of antiapoptotic effectors in vivo under conditions of chronic IL-7 exposure, as substitution of IL-7Ra Y449 prevents the gross overexpression of Bcl-2 and Bcl-xL seen in Tg IL-7; IL-7Ra þ / þ thymocytes, T cells and tumors. Thus, chronic, but not acute, IL-7 exposure in primary T cells may require long-term stimulation of IL-7Ra Y449-dependent signals. This may involve PI3 kinase activation (Lali et al., 2004; Wofford et al., 2008) through subunits other than p110d or other effectors to achieve Bcl-2 upregulation.
STAT5 activation has a pivotal role in IL-7-mediated B-cell development. We have previously shown that STAT5 haploinsufficiency protects from Tg IL-7 tumors (Abraham et al., 2005) , and show herein that activation of this important factor is abrogated by the IL-7Ra 449F mutation in progenitor B cells. Taken together, these findings indicate that STAT5, an essential mediator of lymphoid development, has an essential role in lymphoid transformation. It remains to be addressed whether Em-myc tumorigenesis requires STAT5 activation directly or whether IL-7Ra-mediated signals other than STAT5, such as sustained stimulation of the PI3 kinase/Akt pathway through p27 kip1 or other metabolic effectors regulating glucose metabolism, contribute to tumor formation.
Overall, our genetic analyses show that interference with IL-7Ra Y449 signaling has profound effects on the transformation of T-and B-lymphocyte lineages. Through analysis of IL-7Ra 449F mice in the context of oncogene overexpression, we have shown that IL-7Ra Y449 mutation negates the ability of IL-7 to transform CD8 T cells by preventing the skewed expression of Bcl-2 family members. Surprisingly, this mutation has a significant effect on the emergence of c-Myc-induced tumors by decreasing B-cell viability independent of Bcl-2 and interfering with Myc-induced proliferation. Thus, disruption of IL-7Ra signaling has dramatic effects on disease outcome.
Materials and methods

Mice
IL-7Ra
449F mice were generated by homologous recombination . Briefly, wt exons were replaced with the Y449F mutated version, resulting in mutant receptor expression under endogenous promoter control. Tg IL-7 mice (IL-7 overexpressed in B and T cells by a modified IgH chain enhancer and promoter) (Rich et al., 1993; Abraham et al., 2005) were backcrossed over 20 generations with C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA). Em-myc mice (c-Myc oncoprotein overexpressed specifically in B cells under control of the c-Myc promoter paired with the Em IgH chain enhancer) (Adams et al., 1985) were on the C57BL/6 background. Each transgenic line was bred with IL-7Ra 449F mice (backcrossed to
